期刊文献+

PTEN基因对血管平滑肌细胞影响的研究进展

Research Progress of PTEN Gene Influence on Vascular Smooth Muscle Cells
暂未订购
导出
摘要 再狭窄严重制约了经皮冠状动脉介入治疗的远期疗效。其病理基础是新生内膜的形成;而血管平滑肌细胞增殖和迁移则是其主要成因。PTEN是至今发现的第一个具有磷酸酶活性的抑癌基因。对细胞的生长、增殖、分化、凋亡、黏附、迁移和血管生长等许多生物学行为有重要影响。近年来,对PTEN的研究逐渐从肿瘤领域延伸到一些非肿瘤领域中,随着研究的深入,人们发现其在再狭窄、心肌肥大、高血压、动脉粥样硬化中也发挥重要的作用。 It is found that the final effect of angioplasty is significantly limited by the high rate of restenosis,which is based on the abnormal proliferation and migration of vascular smooth muscle cells.PTEN is a new tumor suppressor gene discovered in recent years,which is also the first tumor suppressor gene with phosphatase activity found so far,having an important impact on cell growth,proliferation and differentiation,apoptosis,adhesion,migration and blood vessel growth,and many other biological behaviors.Along with the deepening of the study,researchers found it also played an important role in the non-neoplastic diseases,such as restenosis,cardiac hypertrophy,hypertension,and atherosclerosis,etc..
机构地区 皖南医学院
出处 《医学综述》 2011年第22期3392-3395,共4页 Medical Recapitulate
关键词 PTEN 基因 支架 再狭窄 血管平滑肌细胞 PTEN Gene Stand Restenosis Vascular smooth muscle cell
  • 相关文献

参考文献23

  • 1Vassilev D, Doganov A, Gil RJ. The role of angioteusin reeeplor 1 blockers in restenosis prevention after percutaneous eoronary interventions[J]. Kardiol Po1,2010,68 ( 1 ) :97-101.
  • 2Merkely B, Jambrik Z. Drug-eluting balloon in the treatment of a recurrent in-stent restenosis of drug-eluting stent [J].Orv Hetil, 2010,151 (37) :1509-1514.
  • 3Brown DA, Lee E W, Loh IST, et al. A new wave in treatment ot vas- cular occlusive disease: biodegradable stents--clinical experience and scientific principles [ J ]. Vase Interv Radiol, 2009,20 ( 3 ) : 315-324.
  • 4Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy [J]. Cite J, 2011, 75 ( 6 ) : 1287-1296.
  • 5Min SK, Kenagy RD,Clowes AW. Induction of vascular atrophy as a novel approach to treating restenosis [ J ]. Vasc Surg, 2008,47 ( 3 ) :662-670.
  • 6McCall P, Witton CJ, Grimsley S, et al. Is PTEN loss associated with clinical outcome measures in human prostate cancer[ J]. Br J Cancer,2008,99 ( 8 ) : 1296-1301.
  • 7Manna D, Bhardwaj N, Vora MS, et al. Differential roles of phos- phatidylserine, PtdIns (4,5) P2, and PtdIns ( 3,4,5 ) P3 in plasma membrane targeting of C2 domains. Molecular dynamics simula- tion, membrane binding, and cell translocation studies of the PK- Calpha C2 domain[ J]. Biol Chem ,2008,283 (38) :26047-26058.
  • 8Ni Z,Tang J, Cai Z, et al. A new pathway of glucocorticoid action for asthma treatment through the regulation of PTEN expression [ J ]. Respir Res, 2011,12 ( 1 ) :47.
  • 9Hill R, Wu H. PTEN,stem cells, and cancer stem cells [J]. J Biol Chem ,2009,284 (18) : 11755-11759.
  • 10Fan C, He L, Kapoor A, et al. PTEN inhibits BMI1 function in- dependently of its phosphatase activity [ J ]. Mol Cancer, 2009, 8(1):98.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部